StockData
Kestra Medical Technologies, Ltd. logo

Kestra Medical Technologies, Ltd. (KMTS) company profile

KMTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 5/30
$28.27+0.30 (+1.07%)

Close on Nov 17, 2026Market cap $1.68BP/E –Yield –

About Kestra Medical Technologies

Surgical & Medical Instruments & Apparatus, SIC 3841

Kestra Medical Technologies, Ltd. is a medical device and digital healthcare company that develops cardiovascular monitoring and therapy technologies. Its primary offering is the Cardiac Recovery System platform, centered on the ASSURE wearable cardioverter defibrillator. The device continuously monitors cardiac rhythms and delivers defibrillation therapy upon detecting life-threatening ventricular arrhythmias. The platform also includes digital engagement applications and clinical workflow software to support care coordination and clinical insights. The company serves healthcare providers, hospitals, and patients who are at elevated risk of sudden cardiac arrest during recovery.

The company is incorporated in Bermuda and maintains its principal executive offices in Kirkland, Washington. Its commercial activities focus on the United States market. The company distributes its systems through a direct sales and customer service organization, while relying on a limited number of third-party suppliers and contract manufacturers to produce and recondition its devices and components.

Summary of the business section of Kestra Medical Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
Kestra Medical Technologies, Ltd.
Headquarters
Kirkland, WA
Address
3933 Lake Washington Blvd Ne, Suite 200 98033
Phone
(425) 279-8002
Employees
443, Apr 30, 2026
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
D0
Fiscal year ends
April 30
Auditor
PricewaterhouseCoopers LLP, Irvine, California

Stock & identifiers

Ticker
KMTS
Exchange
Nasdaq
IPO date
Mar 6, 2025
Shares outstanding
60M, Sep 11, 2026
Public float
$618.70M, Oct 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1877184
CUSIP
G52441105
FIGI
BBG00QHLL9R5
Share class FIGI
BBG00QHLL9Z6
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Traci S. UmbergerSee Remarks, Director195,825
Brian Daniel WebsterSee Remarks, Director445,215
Timothy P. MoranChief Business Officer63,153
Vaseem MahboobChief Financial Officer60,609
Alfred J. Ford JrChief Commercial Officer99,564
Raymond W. CohenDirector54,790
Elizabeth KwoDirector14,116
Jeffrey Lawrence SchwartzDirector25,186,574
Kevin C. ReillyDirector12,585
Mary Kay LadoneDirector44,724
Conor HanleyDirector13,489
Christopher R. GordonDirector27,019,225
Maxwell BikoffDirector–
Toby AuWerterDirector–

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Brian Webster
President, Chief Executive Officer & Director
$765.00K$5.72M$918.00K$95.97K$7.50M-60%
Traci S. Umberger
General Counsel, Chief Administrative Officer & Director
$500.00K$1.91M$360.00K$93.76K$2.86M-53%
Al Ford
Chief Commercial Officer
$500.00K$1.91M$360.00K$24.42K$2.79M–
Vaseem Mahboob
Chief Financial Officer
$470.00K$1.43M$338.40K$28.20K$2.27M-2%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 6, 2025
Offer price
$17.00
Securities offered
11,882,352
Gross proceeds
$202.00M
Exchange
Nasdaq
First trading day
Mar 6, 2025
First-day close
$21.84+28.5%
Lock-up ends (est.)
Sep 2, 2025

“Per Share Total Public offering price $ 17.00 $ 201,999,984.00 Underwriting discount (1) $ 1.2104 $ 14,382,398.86 Proceeds, before expenses, to us $ 15.7896 $ 187,617,585.14 (1) We refer you to the section titled “Underwriting” for additional information regarding underwriter compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of April 30, 2026, we had over 443 full time team members, substantially all of which are located in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?